Search Results for "Bacterial"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Bacterial. Results 101 to 110 of 344 total matches.
Treatment of Pressure Ulcers
The Medical Letter on Drugs and Therapeutics • Feb 23, 1990 (Issue 812)
).
DEBRIDEMENT — Necrotic tissue retards healing of pressure ulcers and provides a culture
medium for bacterial ...
Pressure is the most critical factor in the development of pressure ulcers; high pressure applied constantly for two hours produces irreversible tissue ischemia and necrosis. Malnutrition, fecal and urinary incontinence, fractures, and a low serum albumin may be additional risk factors. Frequent turning and mobilization of patients, relieving pressure and allowing tissue reoxygenation, are the most effective means of prevention and treatment (PS Goode and RM Allman, Med Clin North Am, 73:1511, Nov 1989).
Augmentin XR
The Medical Letter on Drugs and Therapeutics • Jan 20, 2003 (Issue 1148)
promoted for treatment of
acute bacterial sinusitis and community-acquired pneumonia. Augmentin XR ...
Augmentin XR (GlaxoSmithKline), an oral extended-release combination of amoxicillin and the beta-lactamase inhibitor clavulanic acid, is now being promoted for treatment of acute bacterial sinusitis and community-acquired pneumonia. Augmentin XR contains a higher dose of amoxicillin than Augmentin.
In Brief: Fluoroquinolones and Tendon Injuries
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008 (Issue 1300)
substantial bacterial resistance to this class of drugs and
has been associated with an increase ...
The FDA has added a boxed warning to fluoroquinolone package inserts about tendon injuries that may occur as a result of their use. Tendinitis or tendon rupture may occur rarely with systemic use of any fluoroquinolone, either while the drug is being taken or for up to several months afterwards.Fluoroquinolone-related tendon injury is rare; estimates for its incidence in the general population range from 0.14% to 0.4%. The risk is higher for patients >60 years old and for those taking corticosteroids. For patients with organ transplants, the incidence may be as high as 15%.1 A case-control...
Drugs for Urinary Tract Infections
The Medical Letter on Drugs and Therapeutics • Jul 23, 2012 (Issue 1395)
are more likely to be due
to antibiotic-resistant gram-negative bacilli, enterococci
or Staphylococcus ...
The most recent guidelines from the Infectious
Diseases Society of America (IDSA) and its European
counterpart on the choice of antimicrobials for treatment
of uncomplicated urinary tract infections (UTIs) in
non-pregnant women focus on the unnecessary use of
fluoroquinolones to treat uropathogens that are
increasingly becoming resistant to them. Resistance
of Escherichia coli to ciprofloxacin in the US has
increased from 3% in 2000 to 17.1% in 2010.
Treatment of Clostridioides difficile Infection
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021 (Issue 1632)
include
exposure to antibacterial drugs (particularly clindamycin,
third- or fourth-generation ...
Clostridioides (formerly Clostridium) difficile infection
(CDI) is the most common infectious cause of
healthcare-associated diarrhea in adults. Guidelines
on management of CDI have recently been updated.
Intravenous Ciprofloxacin
The Medical Letter on Drugs and Therapeutics • Aug 09, 1991 (Issue 850)
the first fluoroquinolone antibiotic to become available in the USA in an intravenous (IV) formulation ...
Ciprofloxacin, previously available orally (Cipro - Medical Letter, 30:11, 1988) and for ophthalmic use (Ciloxan - Medical Letter, 33:52, May 31, 1991), is now the first fluoroquinolone antibiotic to become available in the USA in an intravenous (IV) formulation. Cipro I.V. (Miles) is being promoted as an alternative to third-generation cephalosporins, aminoglycosides, and other drugs used for treatment of serious infections.
Addendum: Doxycycline for Young Children?
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016 (Issue 1497)
spotted fever, is
seldom fatal and can be treated with antibiotics other than
doxycycline. A single dose ...
A reader commenting on our Treatment of Lyme Disease article (Med Lett Drugs Ther 2016; 58:57) objected to a footnote in the table advising against use of doxycycline in children <8 years old. This warning has been included in the labeling of all tetracyclines since 1970 when it was recognized, after decades of use, that these drugs caused permanent staining and enamel hypoplasia of developing teeth. The CDC recently stated that short courses of doxycycline, which was first marketed in the US in 1967 and has less affnity for calcium than other tetracyclines, have not been shown to cause...
Treatment of Clostridium Difficile Infection
The Medical Letter on Drugs and Therapeutics • Feb 21, 2011 (Issue 1358)
a precipitating antibiotic should have the antibiotic discontinued,
if possible, or switched to another ...
Clostridium difficile infection (CDI) is the most common infectious cause of healthcare-associated diarrhea in adults. The incidence and severity of CDI have increased in recent years with the emergence of an epidemic virulent strain (NAP1/BI/027). Common risk factors include admission to a healthcare facility, increasing age and severity of underlying illness, gastric acid suppression and exposure to antimicrobials, particularly clindamycin, ampicillin, cephalosporins or fluoroquinolones. Patients who develop CDI while receiving a precipitating antibiotic should have the antibiotic...
Aerosolized Deoxyribonuclease for Cystic Fibrosis
The Medical Letter on Drugs and Therapeutics • Apr 15, 1994 (Issue 920)
. It requires a nebulizer to produce an aerosol mist for inhalation.
STANDARD TREATMENT — Bacterial growth ...
Recombinant human deoxyribonuclease I (rhDNase; dornase alfa; Pulmozyme - Genentech), an enzyme that hydrolyzes extracellular DNA, is now available as a purified solution to decrease the viscosity of sputum in patients with cystic fibrosis. It requires a nebulizer to produce an aerosol mist for inhalation.
Drugs for Helicobacter pylori Infection
The Medical Letter on Drugs and Therapeutics • Jul 17, 2017 (Issue 1525)
, or antibiotics. Patients should not take a PPI
for at least 1-2 weeks or a bismuth-containing product ...
About 50% of the world’s population is infected with
Helicobacter pylori. These gastric bacteria can cause
chronic inflammation and have been associated with
development of gastritis, peptic ulcer disease, gastric
adenocarcinoma, and gastric mucosa-associated
lymphoid tissue (MALT) lymphoma. Eradication of H.
pylori can promote gastric healing, prevent recurrence
of duodenal and gastric ulcers, and reduce the
incidence of gastric cancer. Guidelines for treatment
of H. pylori infection were updated recently.
